21 mutation assays are included in this panel. These assays are able to detect the ~30 most frequently identified
EGFR mutations including P-loop and activation loop point mutations, kinase domain deletion, and insertion
4 mutation assays are included in this panel for the most frequently identified ERBB2 activating mutations. These
mutations cluster in the ERBB2 kinase domain region.
12 mutation assays are included for PDGFR-A in this panel. These assays detect the most frequently identified
PDGFR-A gain-of-function mutations, including deletion, point mutation, and deletion-insertion mutations in regions
p.D842_S847, and p.R554_E571, and the point mutations p.N659Y and p.T674I.
4 mutation assays are included in this panel to cover the most frequently identified FLT3 mutations. These include
point mutations and a deletion mutation in the activation loop portion of the sequence, and an insertion mutation in
the juxtamembrane region of the coding sequence.
27 mutation assays are included for KIT in this panel. These assays detect the most frequently identified KIT gain-offunction mutations, such as the D816V point mutation, the exon 11 (juxtamembrane domain) deletion and point
mutations, an exon 9 insertion mutation, and exon 13 point mutations.
The assays included in this panel detect the most frequently identified c-MET gain-of-function mutations, such as the
tyrosine kinase domain and juxtamembrane domain point mutations.
12 mutation assays are included for FGFR2 and FGFR33 in this panel. These assays detect the most frequently
identified kinase domain mutations and non-kinase domain (e.g. extracellular domains such as the hinge region and
IgG-like domain) mutations. Some of the somatic mutations included have congenital correlates that are involved in